Physician profile
Jane M Simpson
NPI 1780110049
$10,727.53
in general payments reported to CMS, 2019-2025
17 companies · $378 in 2025
The $378 reported for 2025 was more than what 89% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $422 · 2021: $218 · 2022: $269 · 2023: $5,500 · 2024: $3,942 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,330 · Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,329.64 |
| Food and Beverage | $489.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $9,359.65 | 2022-2024 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $480.70 | 2020-2025 | |
| Edwards Lifesciences Corporation | $153.14 | 2022 | |
| Gilead Sciences, INC. | $118.27 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.30 | 2024-2025 | Fruzaqla, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $85.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.64 | 2020 | |
| Merck Sharp & Dohme LLC | $52.84 | 2025 | Keytruda, Lynparza |
| Genzyme Corporation | $52.83 | 2025 | |
| Incyte Corporation | $50.22 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Daiichi Sankyo INC. | $49.28 | 2024-2025 | Vanflyta, Injectafer |
| Janssen Biotech, INC. | $41.33 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Regeneron Healthcare Solutions, INC. | $31.81 | 2025 | Libtayo |
| Abbvie INC. | $29.35 | 2025 | |
| Genentech USA, INC. | $29.11 | 2025 | Itovebi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20.88 | 2024 | |
| Puma Biotechnology, INC. | $18.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.